Top Markets
Coin of the day
Genflow Biosciences Plc Genflow Biosciences Plc

Genflow Biosciences Plc

GENF
Hisse Senetlerindeki Sıralama #40421
Genflow Biosciences plc, together with its subsidiaries, engages in the... Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducing the incidence of age-related diseases. Its lead drug candidate is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-1003, a topical delivery of SIRT6 to the fibroblasts in the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005, which addresses mitochondrial dysfunction observed in sarcopenia for muscle health and combat sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company has collaborative research agreements with Revatis SA and EXO Biologics for therapy medicinal products. Genflow Biosciences plc was founded in 2020 and is headquartered in London, the United Kingdom.
Hisse Fiyatı
$0.02653368
Piyasa Değeri
$150.29K
Değişim (1 gün)
-4.41%
Değişim (1 yıl)
194.29%
Ülke
GB
Ticaret Genflow Biosciences Plc (GENF)

Kategori

Genflow Biosciences Plc (GENF) için EPS
2026 itibariyle EPS TTM: 0
Genflow Biosciences Plc şirketinin en son finansal raporlarına ve hisse senedi fiyatına göre, şirketin mevcut EPS'si (TTM) 0'dir. 2026 yılı sonunda, şirketin EPS'si 0 idi; bu, 2026 yılındaki EPS olan 0 ile önceki yıla eşit.
Genflow Biosciences Plc için 2026 - 2026 arasındaki EPS geçmişi
Her yıl sonunda EPS
Yıl EPS Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için EPS